ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2024

Corrigendum to 'Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma': [Annals of Oncology 34 (2023) 806-812].

C E Sharon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.